Fosinopril  (Synonyms: SQ28555 free acid)

Fosinopril (SQ28555 free acid) is the ester proagent of angiotensin-converting enzyme (ACE) inhibitor with an IC₅₀ value of 0.18 μM. Fosinopril demonstrates a non-competitive inhibition effect on ACE activity with an K_i value of 1.675 μM^[1][2].

IC50: 0.18 μM^[1]; Ki: 1.675 μM^[2]

Fosinopril (0-100μM; 30 min) partially inhibits the cosedimentation of liposomes and recombinant LPLA2^[1].
Fosinopril (250 nM) shows no inhibition of the soluble esterase activity of LPLA2^[1].
Fosinopril (0.372, 0.744, 1.116 μM) displays a non-competitive inhibition effect on ACE activity with an K_i value of 1.675 μM^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Fosinopril (4.67 mg/kg; p.o.; 4 weeks) downregulates the creatine kinase (CK) and lactate dehydrogenase (LDH) levels and againsts cardiac dysfunction and structural alteration in rat^[3].
Fosinopril (4.67 mg/kg; p.o.; 4 weeks) suppresses cleaved-caspase 3 expression and myocardial apoptosis in AMI rat model^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

563.66

C₃₀H₄₆NO₇P

98048-97-6

福辛普利

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ondetti, M.A., Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation, 1988. 77(6 Pt 2): p. I74-8.  [Content Brief]

  [2]. Piepho, R.W., Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm, 2000. 57 Suppl 1: p. S3-7.  [Content Brief]

  [3]. Sharma, S., et al., The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther, 1999. 6(4): p. 181-9.  [Content Brief]